Full-Time
Principal Software Engineer
Data
Posted on 7/31/2026
Beacon Biosignals
51-200 employees
EEG neurobiomarker platform for trials
Compensation Overview
$190k - $210k/yr
Boston, MA, USA
Remote
Fully remote within the United States.
 Software Engineering (1) |
|---|
Get referred to Beacon Biosignals
See people who can refer or advise you
- At least 10 years of backend development experience, including significant experience in data engineering, data platforms, and infrastructure for data-centric applications.
- Strong proficiency in SQL and production experience with PostgreSQL.
- Proficiency with data streaming and event processing using tools such as Kafka, RabbitMQ, Pulsar, or Amazon Kinesis.
- Strong proficiency in a modern general-purpose programming language.
- Experience deploying and operating services in containerized environments, with familiarity with Kubernetes and Infrastructure as Code tools such as Terraform or Helm.
- Ability to work collaboratively across disciplines.
- Excellent written and verbal communication skills, particularly in asynchronous and remote-friendly environments.
- Guide architecture and solutions for the Beacon Datastore in partnership with engineering leaders, product leaders, and Datastore stakeholders.
- Influence architectural standards across Platform teams.
- Implement features that model best practices.
- Coach team members to develop their skills and uphold standards for data integrity, design soundness, and maintainability.
- Draft RFCs to lead complex feature discovery and technical design phases, solicit and incorporate input, and build alignment on development decisions.
- Experience with or interest in using large language model-assisted or agentic coding tools in a production setting.
- Proficiency in the Datastore-specific stack of SQL, TypeScript, or Julia is not required, but willingness to learn quickly is valued.
Beacon Biosignals develops an EEG-based neurobiomarker platform for precision medicine in neurology and psychiatry. Its core offering provides quantitative assessments of how treatments affect EEG and sleep data to speed up clinical trials and inform dose selection. By analyzing EEG signals alongside PK/PD relationships, the platform helps identify dosing that achieves the best balance of efficacy and safety, supporting the development of new therapies. The company differentiates itself through its proprietary EEG biomarkers and a focus on integrating brain activity data into trial design, enabling closer monitoring of treatment impact for biopharma, academic medical centers, and neurotechnology developers. Beacon Biosignals aims to advance personalized treatment for neurological and psychiatric diseases and improve the efficiency of clinical development in precision medicine.
Company Size
51-200
Company Stage
Series B
Total Funding
$127.5M
Headquarters
Boston, Massachusetts
Founded
2019
Get referred to Beacon Biosignals
See people who can refer or advise you
Simplify's Take
What believers are saying
- April 6, 2026 Series B extension added $11 million and Samsung Next.
- November 19, 2025 Takeda expansion promises up to $109 million in milestones.
- December 16, 2025 Harmony deal and SLEEP 2026 data expand hypersomnia traction.
What critics are saying
- Takeda and Harmony dominate validation; partner pullback would crush 2027 revenue visibility.
- Beacon depends on pharma accepting EEG endpoints; failed trials kill biomarker commercialization.
- FDA or algorithm-performance setbacks could block Waveband-driven trials and erase Beacon’s core moat.
What makes Beacon Biosignals unique
- Beacon’s FDA-cleared Waveband enables PSG-quality at-home EEG, not consumer proxy signals.
- Beacon’s 2025-2026 platform spans neurology, psychiatry, and sleep medicine with one dataset.
- Beacon’s biomarker stack targets clinical endpoints and PK/PD, not only monitoring.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Equity
Paid Vacation
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↓ -7%1 year growth
↓ -9%2 year growth
↓ -6%Beacon Biosignals showcases advanced AI sleep tech and clinical data at SLEEP 2026. Beacon Biosignals participated in SLEEP 2026, engaging clinicians, researchers and sleep medicine leaders. The company highlighted multiple presentations focused on automated sleep staging algorithms, machine learning-based arousal detection and a large-scale EEG foundation model designed for multi-device sleep analytics. Beacon also presented validation data for its Waveband device in hypersomnia disorders, developed in collaboration with Takeda and featured in an oral presentation, according to the company. For investors, the activity suggests ongoing progress toward building clinically relevant evidence around Beacon's digital biomarker and EEG analytics platform that could support future commercialization or partnership opportunities in sleep medicine and neurology. The emphasis on expert-level algorithm performance and large-scale EEG models indicates an effort to differentiate through technical depth and scalability, potentially positioning the business to serve biopharma trials and clinical endpoints. The company also promoted meeting availability at the conference as part of its business development outreach.
Beacon Biosignals targets neurology trial partners with fda-cleared Waveband EEG at AAN 2026. Last updated: April 20, 2026 Beacon Biosignals is participating in the 2026 American Academy of Neurology Annual Meeting in Chicago. The company is showcasing its Waveband device, a novel technology for electroencephalogram (EEG) signal acquisition and analysis. This event marks a significant opportunity for the company to present its advancements in brain signal technology to a key audience of neurologists and researchers. * Beacon Biosignals' Waveband device is designed for advanced EEG signal acquisition and analysis. The device aims to provide more accurate and efficient data collection for neurological studies. The company's presence at the American Academy of Neurology Annual Meeting signifies its commitment to developing and promoting innovative solutions in the field of neurology. This participation allows for direct engagement with medical professionals and potential collaborators. The meeting is a premier event for showcasing the latest research and technologies in neurology.
Beacon Biosignals raises $11M; brings Series B financing to over $97M. April 6, 2026 Beacon Biosignals, a Boston, MA-based company leveraging brain data to advance human health, raised an $11m extension to its Series B financing, bringing the funding round to $97m the cumulative funding to over $132m. The upsized round included new investors JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next. This financing builds on Beacon's previously announced $86m Series B, led by a syndicate of leading healthcare and technology investors, including Innoviva, GV (Google Ventures), S32, Catalio Capital Management, General Catalyst, Logos Capital, Casdin Capital, Indicator Ventures and others. The company intends to use the funds to further accelerate its mission to transform brain health through scalable, at-home EEG and advanced analytics, powering the next generation of diagnostics, clinical trials, and precision medicine. Led by Jacob Donoghue, CEO, Beacon Biosignals combines FDA-cleared wearable EEG technology with advanced AI to capture and analyze real-world neural data, enabling breakthroughs across neurology, psychiatry, and sleep medicine. The platform provides clinicians and biopharma partners with objective measures of brain function that accelerate research, improve diagnostics, and guide new treatments. 06/06/2026
Beacon Biosignals has extended its Series B financing to $97 million, bringing total funding to over $132 million. The upsized round includes new investors JSL Health, Palo Santo VC, Kicker Ventures and Samsung Next. The Boston-based company combines FDA-cleared wearable EEG technology with AI to capture and analyse brain data for neurology, psychiatry and sleep medicine applications. The additional capital will accelerate Beacon's development of at-home EEG and advanced analytics for diagnostics, clinical trials and precision medicine. The original $86 million Series B was led by healthcare and technology investors including Innoviva, GV, S32, Catalio Capital Management, General Catalyst, Logos Capital, Casdin Capital and Indicator Ventures. The platform provides clinicians and biopharma partners with objective measures of brain function.
Beacon Biosignals upsizes Series B financing to over $97 million. GlobeNewswire | Beacon Biosignals Today at 3:30am PDT BOSTON, April 06, 2026 (GLOBE NEWSWIRE) - Beacon Biosignals today announced an extension to its Series B financing, bringing the funding round to $97 million and the company's cumulative funding to over $132 million. The upsized round includes new investors JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next. This financing builds on Beacon's previously announced $86 million Series B, led by a syndicate of leading healthcare and technology investors, including Innoviva, GV (Google Ventures), S32, Catalio Capital Management, General Catalyst, Logos Capital, Casdin Capital, Indicator Ventures and others. The new capital will further accelerate Beacon's mission to transform brain health through scalable, at-home EEG and advanced analytics, powering the next generation of diagnostics, clinical trials, and precision medicine. "This milestone reflects strong momentum behind our vision to make brain health measurable, scalable, and actionable," said Jacob Donoghue, CEO of Beacon Biosignals. "We're grateful for the support of our new and existing investors as we build the future of brain health." "Beacon is uniquely positioned to unlock the potential of brain data at scale," said Daniel Goldberg, Managing Director at Palo Santo. "Their combination of clinical-grade EEG and advanced analytics is enabling a new era of discovery and precision in neuroscience. As novel therapeutics like psychedelics reshape the treatment landscape for psychiatric disease, platforms like Beacon's will be critical for objectively measuring brain-based outcomes and accelerating development." About Beacon Biosignals Beacon Biosignals is unlocking the power of brain data to advance human health. The company combines FDA-cleared wearable EEG technology with advanced AI to capture and analyze real-world neural data, enabling breakthroughs across neurology, psychiatry, and sleep medicine. The Beacon Platform provides clinicians and biopharma partners with objective measures of brain function that accelerate research, improve diagnostics, and guide new treatments. Learn more at www.beacon.bio. Media Contact: Isabella Lazzareschi, Beacon Biosignals [email protected] This is a paid placement. For further inquiries, please contact GlobeNewswire directly.